Cart
sales@molnova.com
Telratolimod
CAS No. 1359993-59-1
Telratolimod( MEDI9197 | 3M-052 )
Catalog No. M26840 CAS No. 1359993-59-1
Telratolimod is a toll-like receptors 7/8 agonist. It has an antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 223 | In Stock |
|
| 5MG | 335 | In Stock |
|
| 10MG | 500 | In Stock |
|
| 25MG | 806 | In Stock |
|
| 50MG | 1098 | In Stock |
|
| 100MG | 1485 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTelratolimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionTelratolimod is a toll-like receptors 7/8 agonist. It has an antitumor activity.
-
DescriptionTelratolimod is a toll-like receptors 7/8 agonist. It has an antitumor activity.(In Vivo):Telratolimod (50 μg) suppresses the tumor volume and more effectively blocks tumor growth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs the survival of mice bearing large tumors .
-
In VitroTelratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.
-
In VivoTelratolimod (50 μg) inhibits the tumor volume, and more potently blocks tumor gowth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors.
-
SynonymsMEDI9197 | 3M-052
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorLpxC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1359993-59-1
-
Formula Weight593.901
-
Molecular FormulaC36H59N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (105.24 mM)
-
SMILESCCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ushiyama F, et al. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532. Bioorg Med Chem. 2021;30:115964.
molnova catalog
related products
-
Tomaralimab
Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting TLR2, used to study myelodysplastic syndromes (MDS).
-
CU-CPT17e
CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).
-
SM-276001
SM-276001 is a potent selective agonist of TLR7,and is an orally active interferon (IFN) inducer.
